We are at a hinge moment in the biopharmaceutical industry, where we are seeing profound changes in drug discovery and development powered by the union of technology and biotechnology. At Amgen we have been preparing for this moment for over a decade, investing in the power of artificial intelligence (AI), data science and other technologies to create the next generation of medicines that will bring the most value to patients.
AMPLIFY is a novel protein language model (pLM) developed by Amgen and Mila – Quebec Artificial Intelligence Institute. By learning the language of proteins, pLMs have the potential to predict protein properties and design new protein therapeutics. AMPLIFY outperforms existing pLMs on protein design tasks with only a fraction of the parameters, or training variables, enhancing both efficiency and accuracy. Amgen and Mila have made AMPLIFY's pre-training codebase, data and model checkpoints open source to democratize pLM training and accelerate protein research and drug discovery. For more information, visit bioRxiv.
